Klinisk Biokemi i Norden · 1 2016
| 43
33. Cordell HJ. Epistasis: what it means, what it
doesn’t mean, and statistical methods to detect
it in humans. HumMol Genet 2002;11:2463-8.
34. CARDIoGRAMplusC4DConsortium, Delou-
kas P, Kanoni S, Willenborg C, Farrall M, Assi-
mes TL, et al. Large-scale association analysis
identifies new risk loci for coronary artery
disease. Nat Genet 2013;45:25-33.
35. Coronary Artery Disease (C4D) Genetics
Consortium. A genome-wide association
study in Europeans and South Asians identi-
fies five new loci for coronary artery disease.
Nat Genet 2011;43:339-44.
36. Schunkert H, König IR, Kathiresan S, Reilly
MP, Assimes TL, Holm H, et al. Large-
scale association analysis identifies 13 new
susceptibility loci for coronary artery disease.
Nat Genet 2011;43:333-8.
37. Urbonaviciene G, Shi GP, Urbonavicius S,
Henneberg EW, Lindholt JS. Higher cys-
tatin C level predicts long-term mortality
in patients with peripheral arterial disease.
Atherosclerosis 2011;216:440-5.
38. Slinin Y, Peters KW, Ishani A, Yaffe K, Flink
HA, Stone KL, et al. Cystatin C and cognitive
impairment 10 years later in older women. J
Gerontol A Biol Sci Med Sci 2015;70:771-8.
39. Ito H, Pacold IV, Durazo-Arvizu R, Lui K,
Shilipak MG, Goff DC Jr, et al. The effect
of including cystatin C or creatinine in a
cardiovascular risk model for asymptomatic
individuals: the multi-ethnic study of athero-
sclerosis. Am J Epidemiol 2011;174:949-57.
40. Melander O, Newton-Cheh C, Almgren P,
Hedblad B, Berglund G, Engström G, et al.
Novel and conventional biomarkers for pre-
diction of incident cardiovascular events in
the community. JAMA 2009;302:49-57.
41. Ni L, Lü J, Hou LB, Yan JT, Fan Q, Hui R, et
al. Cystatin C, associated with hemorrhagic
and ischemic stroke, is a strong predictor of
the risk of cardiovascular events and death in
Chinese. Stroke 2007;38:3287-8.
42. Menon V, Shlipak MG, Wang X, Coresh J,
Greene T, Stevens L, et al. Cystatin C as a risk
factor for outcomes in chronic kidney disease.
Ann Intern Med 2007;147:19-27.
43. O’Hare AM, Newman AB, Katz R, Fried LF,
Stehman-Breen, Seliger SL, et al. Cystatin C
and incident peripheral arterial disease events
in the elderly: results from the Cardiovascular
Health Study. Arch Int Med 2005;165:2666-70.
44. Knight EL, Verhave JC, Spiegelman D, Hil-
lege HL, de Zeeuw, Curhan GC, de Jong PE.
Factors influencing serum cystatin C levels
other than renal function and the impact
on renal function measurement. Kidney Int
2004;65:1416-21.
45. Evangelopoulos AA, Vallianou NG, Bount-
ziouka VP, Giotopoulou AN, Bonou MS,
Barbetseas J, et al. The impact of demo-
graphic characteristics and lifestyle in the
distribution of cystatin C values in a healthy
greek adult population. Cardiol Res Pract
2010;2011:163281.
46. Poręba R, Gać P, Poręba M, Antonowicz-
Juchniewicz J, Andrzejak R. Relation between
occupational exposure to lead, cadmium,
arsenic and concentration of cystatin C. Toxi-
cology 2011;283:88-95.
47. Fox CS, Larson MG, Leip EP, Culleton B,
Wilson PW, Levy D. Predictors of new-onset
kidney disease in a community-based popula-
tion. JAMA 2004;291:844-50.
48. Svensson-Färbom P, Almgren P, Hedblad
B, Engström G, Persson M, Christensson
A, Melander O. Cystatin C is not causally
related to coronary artery disease. PloS One
2015;10:e0129269.
49. S. W. van der Laan1 TF, J. van Setten1,3, P.
I. W. de Bakker3,4, G. Pasterkamp1, J. Ärn-
löv2, M. V. Holmes5, F. W. Asselbergs3,6,7,8
on behalf of the Cystatin C MR Consortium.
Cystatin C and cardiovascular disease: a Men-
delian randomization study. 2014.
50. M. Magnusson JM, G. Engstrom, M. Persson,
P. Nilsson, A. Christensson, O. Melander,.
Cystatin C is not causally associated with dia-
betes or the metabolic syndrome. European
heart journal 2015.
51. Chrysochou C, Kalra PA. Epidemiology and
natural history of atherosclerotic renovascular
disease. Progr Cardiovasc Dis 2009;52:184-95.
